Benzestrol manufactured by Schieffelin & Co. Pharmaceutical New-York

Many different companies manufactured and marketed the DES drug under more than 200 different brand names

Benzestrol manufactured by Schieffelin & Co. Pharmaceutical New-York on Flickr

DES was sold under many names including Distilbène®, Stilbetin®, Stilboestrol-Borne®, Benzestrol®, Chlorotrianisene®, Estrobene® and Estrosyn® to name just a few.

DES DiEthylStilbestrol Resources

Are we going to ignore DES Studies Results like we did in 1939?

Scary and Shocking Facts about Diethylstilbestrol

Five Scary and Shocking Facts about DiethylstilbestrolThird-generation children, the offspring of DES daughters and DES sons, are just beginning to reach the age when relevant health problems can be studied.  Funding for more research is critically needed to continue to look for evidence of reproductive abnormalities and cancers among third-generation DES women and men to ensure they receive appropriate follow-up care. ”

Read Five Scary and Shocking Facts about Diethylstilbestrol.

DES DiEthylStilbestrol Resources

Ben Goldacre @bengoldacre LiveChat Comments on Big Pharma via @DES_Journal

Live Chat Transcript With Ben Goldacre: How Bad Is the Pharma Industry?In medicine, we need to see all the results, positive and negative, to get a clear understanding of the overall risks and benefits of a treatment. If we only see the positive results, with the less flattering results withheld, then we get an exaggerated picture of the benefits. This can lead to bad treatment decisions. We can be misled into thinking an ineffective treatment is actually effective, meaning a patient is exposed to side effects unnecessarily, or deprived of another effective treatment that they would have had instead. We can be misled into thinking it’s worth enduring side effects for a large benefit, when in reality the benefits are only modest “.

Read Live Chat Transcript With Ben Goldacre:
How Bad Is the Pharma Industry?

More posts about Ben Goldacre

Breast Cancer Prevention : Time to take Responsibility

An Urgent Mandate for Breast Cancer Prevention

Enough Already! An Urgent Mandate for Breast Cancer Prevention” 29 percent of all cancers in women start in the breast… ”

” These are not just statistics, data points filling up graphs and tables. These are our mothers, sisters, friends and neighbors — women in the prime of their lives with so much at stake and so much more to give: children, spouses and partners, promising careers, civic service, etc… ”

” We’re now exposed to vast and widespread use of hormonally active chemicals that didn’t exist a hundred years ago: pesticides, flame retardants, plasticizers (like bisphenol A), antibiotics in livestock feed, hormones in the beef and dairy cattle industry, and pharmaceutical hormones for women, as just a few examples. What comes around goes around … ”

Read Enough Already! An Urgent Mandate for Breast Cancer Prevention by Marisa Weiss, M.D., 03/04/2013.

Génération Médicaments: Fille Distilbène, Garçon Médiator

Médocs par Olivero, dessin de presse

Médocs par Olivero, dessin de presse.
  • Retrouvez cette image ainsi que l’album DES Art sur Flickr.
Le Distilbène DES, en savoir plus

Nr0b2 Molecular Mechanism underlying many of the Harmful Effects of DES on Male Mice

The orphan nuclear receptor small heterodimer partner mediates male infertility induced by diethylstilbestrol in mice

The sexual function of male rodents can be impaired by in utero and/or neonatal exposure to external molecules that disrupt normal hormone functioning, giving rise to concerns that low-level exposure to such molecules might cause similar effects in humans. Examples of such molecules include the synthetic nonsteroidal estrogen DES, which was used as a treatment for various diseases until the mid 1990s, and BPA, which is found, among other places, in some plastic containers. “

2009 Study Abstract

Studies in rodents have shown that male sexual function can be disrupted by fetal or neonatal administration of compounds that alter endocrine homeostasis, such as the synthetic nonsteroidal estrogen diethylstilbestrol (DES). Although the molecular basis for this effect remains unknown, estrogen receptors likely play a critical role in mediating DES-induced infertility. Recently, we showed that the orphan nuclear receptor small heterodimer partner (Nr0b2), which is both a target gene and a transcriptional repressor of estrogen receptors, controls testicular function by regulating germ cell entry into meiosis and testosterone synthesis. We therefore hypothesized that some of the harmful effects of DES on testes could be mediated through Nr0b2. Here, we present data demonstrating that Nr0b2 deficiency protected mice against the negative effects of DES on testis development and function. During postnatal development, Nr0b2-null mice were resistant to DES-mediated inhibition of germ cell differentiation, which may be the result of interference by Nr0b2 with retinoid signals that control meiosis. Adult Nr0b2-null male mice were also protected against the effects of DES; however, we suggest that this phenomenon was due to the removal of the repressive effects of Nr0b2 on steroidogenesis. Together, these data demonstrate that Nr0b2 plays a critical role in the pathophysiological changes induced by DES in the mouse testis.

Sources and more information
More DES DiEthylStilbestrol Resources

The FDA planning to step up to the Social Media Plate in 2013

FDA CDRH 2013 Strategic Priorities Bring Light to Patient Access

FDA CDRH 2013 Strategic Priorities Bring Light to Patient Access

2013 could be the year that FDA steps up to the social media plate to address the use of the internet and social media tools in promoting drugs and devices and accessing information.

Could these FDA strategies improve transparency and patients access to information?
Read FDA CDRH 2013 Strategic Priorities Bring Light to Patient Access by Christopher Ford, MARCH 4, 2013.

Silent Thalidomide could affect Thousands of Australian Women

Media Ripple Effect ; from UK to OZ

‘Silent Thalidomide’ could affect thousands of Australian women

It was touted as a wonder drug that could prevent miscarriages, but 40 years on, experts fear DES may be causing cancer in up to three generations of women

January 2012, when the ripple effects of the Independent on Sunday reached Australia… read ‘Silent Thalidomide’ could affect thousands of Australian women, January 23, 2012.

More DES DiEthylStilbestrol Resources

DiEthyl-Stilbestrol 25 mg DES Drug Tablets

Did your mum take DES? These pills were manufactured by Eli Lilly

DiEthyl-Stilbestrol 25 mgDid your mum take DES? This DiEthyl-Stilbestrol 25mg drug tablets image could help you ask and find out…

See more DES drugs photo set on flick DES Diethylstilbestrol's photostream on Flickr

If you already have a flick account, add us as a contact
Email your photos to with a short description and title :-) – it’s Time for Actions: did you SIGN THE PETITION ?

More DES DiEthylStilbestrol Resources

Use of Robots for Hysterectomy Soars, but with Little Benefit

Why are gynecologists pushing robotic hysterectomies?

Use of Robots for Hysterectomy Soars, but with Little BenefitRobotically assisted hysterectomy increased dramatically from 2007 to 2010, despite higher cost and similar complication rates compared with laparoscopic procedures, a review of data from more than 400 hospitals showed. “

Read Use of Robots for Hysterectomy Soars, but with Little Benefit
by Charles Bankhead, MedPage Today.

Comparative Effectiveness Research on Robotic Surgery

During the last 10 years, the use of robotic-assisted surgery has substantially increased, beginning with urologic procedures and expanding to include gynecologic procedures and many others. Robotic-assisted surgery is a type of minimally invasive procedure that in fact facilitates laparoscopic surgery. Both approaches provide benefits compared with open surgery, including smaller incisions, shorter hospital stays, less postoperative pain, and possibly quicker return to function. As of 2009, more than 200 000 robotically assisted operations had been performed worldwide. The reason for its rapid dissemination in the United States may be linked to a number of converging factors, including better ergonomics for the surgeon, marketing campaigns, and the national fascination with technology and innovation. Under other circumstances, this might be an unparalleled success story of US medical ingenuity. However, critics of robotic surgery claim that it is more expensive without providing a concomitant benefit. Sources.

Robotically Assisted vs Laparoscopic Hysterectomy Among Women With Benign Gynecologic Disease


Although robotically assisted hysterectomy for benign gynecologic conditions has been reported, little is known about the incorporation of the procedure into practice, its complication profile, or its costs compared with other routes of hysterectomy.

To analyze the uptake of robotically assisted hysterectomy, to determine the association between use of robotic surgery and rates of abdominal and laparoscopic hysterectomy, and to compare the in-house complications of robotically assisted hysterectomy vs abdominal and laparoscopic procedures.

Design, Setting, and Patients
Cohort study of 264 758 women who underwent hysterectomy for benign gynecologic disorders at 441 hospitals across the United States from 2007 to 2010.

Main Outcome Measures
Uptake of and factors associated with utilization of robotically assisted hysterectomy. Complications, transfusion, reoperation, length of stay, death, and cost for women who underwent robotic hysterectomy compared with both abdominal and laparoscopic procedures were analyzed.

Use of robotically assisted hysterectomy increased from 0.5% in 2007 to 9.5% of all hysterectomies in 2010. During the same time period, laparoscopic hysterectomy rates increased from 24.3% to 30.5%. Three years after the first robotic procedure at hospitals where robotically assisted hysterectomy was performed, robotically assisted hysterectomy accounted for 22.4% of all hysterectomies. The rates of abdominal hysterectomy decreased both in hospitals where robotic-assisted hysterectomy was performed as well as in those where it was not performed. In a propensity score–matched analysis, the overall complication rates were similar for robotic-assisted and laparoscopic hysterectomy (5.5% vs 5.3%; relative risk [RR], 1.03; 95% CI, 0.86-1.24). Although patients who underwent a robotic-assisted hysterectomy were less likely to have a length of stay longer than 2 days (19.6% vs 24.9%; RR, 0.78, 95% CI, 0.67-0.92), transfusion requirements (1.4% vs 1.8%; RR, 0.80; 95% CI, 0.55-1.16) and the rate of discharge to a nursing facility (0.2% vs 0.3%; RR, 0.79; 95% CI, 0.35-1.76) were similar. Total costs associated with robotically assisted hysterectomy were $2189 (95% CI, $2030-$2349) more per case than for laparoscopic hysterectomy.

Conclusions and Relevance
Between 2007 and 2010, the use of robotically assisted hysterectomy for benign gynecologic disorders increased substantially. Robotically assisted and laparoscopic hysterectomy had similar morbidity profiles, but the use of robotic technology resulted in substantially more costs.